{
    "clinical_study": {
        "@rank": "119384", 
        "arm_group": [
            {
                "arm_group_label": "ASP3550  PART 1 and PART 2", 
                "arm_group_type": "Experimental", 
                "description": "Part 1 for 1 year treatment and Part 2 for an extended period of treatment"
            }, 
            {
                "arm_group_label": "Goserelin", 
                "arm_group_type": "Active Comparator", 
                "description": "part 1 for 1 year treatment"
            }
        ], 
        "brief_summary": {
            "textblock": "To compare the efficacy and safety of ASP3550  to goserelin acetate in patients with\n      prostate cancer."
        }, 
        "brief_title": "A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer", 
        "completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This study consists of two parts.  The purpose of PART 1 is to test non-inferiority of\n      ASP3550 to goserelin acetate with respect to the cumulative castration rate in terms of\n      serum testosterone when ASP3550 or goserelin acetate is administered for one-year in\n      patients with prostate cancer.\n\n      The patients assigned to receive ASP3550 and completed the treatment in PART 1 are eligible\n      for the treatment in PART 2, and will receive ASP3550 maintenance dose subcutaneously for\n      additional term.  The long-term safety, efficacy  and PK of the continued ASP3550 treatment\n      will be assessed in PART 2."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male patient with histologically confirmed prostate cancer (adenocarcinoma).\n\n          -  Patient in whom endocrine treatment is indicated. Patient having undergoing\n             prostatectomy or radiotherapy with curative intention and has a rising serum PSA (PSA\n             \u2265 2 ng/mL at screening) may be included.\n\n          -  Has a serum testosterone level above 2.2 ng/mL at screening.\n\n          -  Has an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0\n             to 2 at screening.\n\n          -  Has a serum PSA \u2265 2 ng/mL at screening.\n\n          -  Has a life expectancy of at least 12 months.\n\n        Exclusion Criteria:\n\n          -  Previous or present endocrine treatment for prostate cancer. Example: surgical\n             castration, GnRH agonists, GnRH antagonists, antiandrogens or oestrogens, and\n             5\u03b1-reductase inhibitors.\n\n          -  Received a 5\u03b1-reductase inhibitor within 25 weeks preceding screening.\n\n          -  Is a candidate for curative therapy, i.e., radical prostectomy or radiotherapy within\n             12 months.\n\n          -  Has concurrent or a history of poorly controlled severe asthma, anaphylactic\n             reactions, severe urticaria or angioedema.\n\n          -  Has hypersensitivity towards mannitol.\n\n          -  Has a marked prolongation of QT/QTc interval (two consecutive increases to >450 ms in\n             QTc interval at retest) at screening.\n\n          -  Has concurrent or a history of a disease (heart failure, hypokalemia, a family\n             history of QT prolongation syndrome, etc.) that may induce Torsade de Pointes."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "230", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01964170", 
            "org_study_id": "3550-CL-0010"
        }, 
        "intervention": [
            {
                "arm_group_label": "ASP3550  PART 1 and PART 2", 
                "description": "subcutaneous", 
                "intervention_name": "ASP3550", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Goserelin", 
                "description": "subcutaneous", 
                "intervention_name": "Goserelin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Goserelin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "ASP3550", 
            "Prostate cancer"
        ], 
        "lastchanged_date": "October 15, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chubu", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chugoku", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hokkaido", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansai", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kantou", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyushu", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shikoku", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Touhoku", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "ASP3550 Phase III Study - An Open-Label, Active-Controlled, Parallel-Arm Study, Comparing ASP3550 With Goserelin Acetate in Patients With Prostate Cancer -", 
        "overall_contact": {
            "email": "clintrialtrials_info@jp.astellas.com", 
            "last_name": "Clinical Development Administration Dept"
        }, 
        "overall_official": {
            "affiliation": "Astellas Pharma Inc", 
            "last_name": "Medical Director", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Cumulative castration rate of treatment in terms of serum testosterone level", 
            "safety_issue": "No", 
            "time_frame": "Up to one year of the treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01964170"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of castrated subjects in terms of serum testosterone level", 
                "safety_issue": "No", 
                "time_frame": "Up to one year of the treatment"
            }, 
            {
                "measure": "Proportion of castrated subjects in terms of serum testosterone level", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Days 3, 7, and 28"
            }, 
            {
                "measure": "Changes in serum levels of prostate-specific antigen (PSA) over time", 
                "safety_issue": "No", 
                "time_frame": "Up to one year of the treatment"
            }, 
            {
                "measure": "Safety assessed by the incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "up to the end of treatment. approximately for 2 years"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}